Related Content:
Marc Rothenberg, MD, PhD: EoE Receives First FDA Approval with Dupilumab
Systematic Review Suggests Oral JAK Inhibitors Effective in AD
Study Identifies 24 Adverse Events Associated with Secukinumab Treatment
